Trial Profile
Effects of NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) BID and QD vs. Byetta™ Exenatide) BID on Glycemic Control: A Multicenter, 24-Week, Open-Label, Parallel Group Study in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets With Metformin and a Sulfonylurea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 19 May 2009 Actual patient number changed from 372 to 373 as reported by ClinicalTrials.gov.
- 19 May 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
- 04 Jul 2007 Status change